Pharmaceutical compound
| Combination of | |
|---|---|
| Hydrochlorothiazide | Thiazide diuretic |
| Triamterene | Potassium-sparing diuretic |
| Clinical data | |
| Trade names | Dyazide, Maxzide, others |
| Other names | co-triamterzide |
| AHFS/Drugs.com | Professional Drug Facts |
| License data | |
| Pregnancy category |
|
| Routes of administration | By mouth |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| KEGG | |
Hydrochlorothiazide/triamterene, also known as co-triamterzide, is a fixed-dose combination medication of hydrochlorothiazide and triamterene. It is used to treat high blood pressure and edema (swelling). Specifically it is used in those who develop low blood potassium (hypokalemia) when on only hydrochlorothiazide. It is taken by mouth.
Side effects may include nausea, trouble sleeping, dizziness, feeling light headed with standing, kidney problems, allergies, and muscle cramps. Other serious side effects may include high blood potassium. Use in pregnancy and breastfeeding is not generally recommended. Use in those with significant kidney problems is not recommended. It decreases blood pressure mainly by hydrochlorothiazide while triamterene decreases the amount of potassium lost.
The combination was approved for medical use in the United States in 1965. In 2022, it was the 116th most commonly prescribed medication in the United States, with more than 5 million prescriptions.
References
- "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 October 2023.
- ^ "Dyazide- hydrochlorothiazide and triamterene capsule". DailyMed. 31 October 2017. Retrieved 20 August 2020.
- ^ "Maxzide-25- maxzide tablet Maxzide tablet". DailyMed. 20 July 2018. Retrieved 20 August 2020.
- ^ British national formulary : BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 76. ISBN 9780857113382.
- "Dyazide: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Retrieved 20 August 2020.
- "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
- "Hydrochlorothiazide; Triamterene Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
| Diuretics (C03) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Sulfonamides (and etacrynic acid) |
| ||||||||
| Potassium-sparing (at CD) |
| ||||||||
| Osmotic diuretics (PT, DL) | |||||||||
| Vasopressin receptor inhibitors (DCT and CD) | |||||||||
| Other | |||||||||
| Combination products | |||||||||
| |||||||||
| GSK | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Subsidiaries |
| ||||||||
| Predecessors, acquisitions | |||||||||
| Products |
| ||||||||
| People |
| ||||||||
| Litigation | |||||||||
| Other | |||||||||
